Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Rating of "Moderate Buy" from Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $50.40.

Several analysts have commented on TWST shares. The Goldman Sachs Group reduced their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Robert W. Baird lowered their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Finally, Barclays cut their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th.

Twist Bioscience Stock Performance

Shares of TWST stock traded up $1.09 during trading hours on Friday, hitting $34.45. The stock had a trading volume of 1,273,889 shares, compared to its average volume of 979,164. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The firm has a market capitalization of $2.06 billion, a PE ratio of -10.19 and a beta of 2.38. The stock's 50 day moving average is $34.17 and its 200 day moving average is $41.84. Twist Bioscience has a twelve month low of $27.12 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, research analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 2,058 shares of the firm's stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now directly owns 265,460 shares in the company, valued at approximately $10,615,745.40. This trade represents a 0.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,726 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the transaction, the chief executive officer now directly owns 660,966 shares of the company's stock, valued at approximately $27,549,062.88. This trade represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,012 shares of company stock valued at $817,752. 3.01% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc increased its position in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after purchasing an additional 580 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after buying an additional 303 shares in the last quarter. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $43,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $58,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.